Statement Of Cash Flows [Abstract]

PCI Biotech Holding - Filing #5867918

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Interest paid, classified as operating activities
- NOK
1,000 NOK
Interest received, classified as operating activities
1 596 NOK
2 045 NOK
Cash flows from (used in) operating activities
13 758 NOK
14 970 NOK
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
- NOK
- NOK
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities
357,000 NOK
442,000 NOK
Cash flows from (used in) financing activities
357,000 NOK
442,000 NOK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
14 115 NOK
15 412 NOK
Cash and cash equivalents
27 069 NOK
41 184 NOK
56 596 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.